Subacute and chronic prurigo effectively treated with recombination interferon-gamma: implications for participation of Th2 cells in the pathogenesis of prurigo.

Tokura, Y.; Yanagimoto, Hiroaki; Hanaoka, Keiko; Ito, Toshinori; Towyama, K; SACHI, Y.; Tanaka, Masao; Sakamoto, Tatsuo; Sekizuka, Tomomi; Furukawa, Fukumi; Takigawa, Masaharu

doi:10.2340/0001555577231234

Cited by 20 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pathological mechanisms of AD still remain unclear, but immune dysregulation, barrier defects, and cutaneous dysbiosis are demonstrated to be involved and the importance of Th2 cells has been focused [16][17][18]. Several studies have proved the overexpression of some Th2 cytokines (such as IL-4, IL-31) [19,20] in prurigo, suggesting that dupilumab may benefit patients with PN by blocking type 2 inflammation.…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Prurigo Nodularis by Dupilumab: Report of 24 Patients

Dou¹,

Zhao²,

Wang³

et al. 2023

Dermatology

View full text Add to dashboard Cite

Background: Prurigo nodularis (PN) is a chronic pruritic skin disease which is difficult to treat. Current treatment options often lead to limited clinical benefit or severe side effects. Objective: To evaluate the efficacy and safety of dupilumab in the treatment of prurigo nodularis in adults. Method: This study is a retrospective cohort study. Twenty-four adult patients with prurigo nodularis were included and treated with dupilumab. The primary outcomes were the mean reduction in the Investigator’s Global Assessment (IGA) score, and pruritus numeric rating scale (p-NRS) score. Outcomes were assessed at baseline, week 4, week16, and week 36. Results: The study included 24 patients, while 9 (37.5%) were male, and the mean(SD) age of the enrolled patients was 49.88 ± 16.71 years. At the end of treatment, the mean p-NRS score decreased from 7.50 ± 2.21 to 1.41 ± 0.91 (P<0.001), sleeplessness numeric rating scale (s-NRS) score declined from 5.33 ± 3.29 to 0.18 ± 0.59(P <0.001), and Dermatology Life Quality Index (DLQI) score decreased from 13.32 ± 4.88 to 0.91 ± 0.81 (P<0.001). Fourteen (63.6%) patients achieved IGA 0/1 and 21 (95.4%) patients achieved IGA activity 0/1. Among 14 patients who achieved IGA 0/1,10 had an elevated serum IgE level, and patients with a high serum IgE level showed a more remarkable reduction in IGA (r=0.52, P=0.03). Patients with AD responded faster than those without AD (3.76 ± 1.71 weeks vs 6.40 ± 1.67 weeks, P=0.01). Adverse events were recorded in 4/24 (16.6%) patients, with conjunctivitis the most frequent. Conclusion: This study demonstrated that dupilumab is effective and safe for prurigo nodularis and could be a potential therapeutic option.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Prurigo Nodularis by Dupilumab: Report of 24 Patients

Dou¹,

Zhao²,

Wang³

et al. 2023

Dermatology

View full text Add to dashboard Cite

show abstract

Eosinophilic Dermatoses

Katayama

Murota²

2010

Therapy of Skin Diseases

View full text Add to dashboard Cite

Balneophotochemotherapie der Prurigo simplex subacuta

et al. 1999

View full text Add to dashboard Cite

Seventeen patients with extensive subacute prurigo, often resistant to different regimens of prior external and internal therapy, were treated with PUVA bath photochemotherapy (psoralen bath followed by UVA irradiation) using bath water containing 0.5 mg/l of 8-methoxypsoralen (8-MOP). In 15 of 17 patients treated, the skin lesions showed a significant improvement or even complete clearance within 8 weeks of therapy. In two patients, only limited clinical improvement was achieved. Follow-up after 6 weeks revealed sustained improvement in the successfully treated patients. The mean cumulative UVA dose given until clearance was 30.3 (SD +/- 12.6) J/cm2. Therefore, a mean of 24.1 (SD +/- 5.3) PUVA bath treatments was necessary. No side effects were seen except phototoxic reactions in two patients manifested as slight erythema. The results of this trial show that PUVA bath photochemotherapy with 8-MOP is an effective therapeutic alternative to other known therapies in subacute prurigo. Compared to oral PUVA therapy or other topical and systemic treatments, PUVA bath photochemotherapy with 8-MOP shows an excellent efficiency-side effect ratio. The clearance of chronic skin lesions refractive to other topical or systemic treatments by PUVA bath photochemotherapy with 8-MOP demonstrates that this therapy can be even superior to other common therapeutic modalities used for subacute prurigo.

show abstract

Subacute and chronic prurigo effectively treated with recombination interferon-gamma: implications for participation of Th2 cells in the pathogenesis of prurigo.

Abstract: Subacute and chronic prurigo is notoriously resistant to usual therapies. Four of five patients with a subacute or chronic form of prurigo responded well to daily intravenous injections of recombinant interferon-gamma (rIFN-gamma) (0.25-2 x 10(6) Japan Reference Unit (JRU

Cited by 20 publications

References 0 publications

Successful Treatment of Prurigo Nodularis by Dupilumab: Report of 24 Patients

Successful Treatment of Prurigo Nodularis by Dupilumab: Report of 24 Patients

Eosinophilic Dermatoses

Balneophotochemotherapie der Prurigo simplex subacuta

Contact Info

Product

Resources

About